Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s PFIC Gene Therapy Programs
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Vivet and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for WD
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020.
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation.
PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
Vivet is very happy to share the March 2020
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board.
PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare
